The “Cockroach” Portfolio Just Had Its Best 3 Months Possibly Ever
Call it the “safe” portfolio, the “bulletproof” portfolio, or the “cockroach” portfolio, this portfolio just had its best three months possible ever. CLICK HERE.
These Non-Tech Dividend Paying Stocks Have Been Soaring This Year
While the market seems to have fully recovered from the March selloff, most of the heavy lifting has been done by a handful of big… Read More »These Non-Tech Dividend Paying Stocks Have Been Soaring This Year
5 Stock Picks For Contrarians To “Nibble At Value” – And Profit From The Post-Pandemic Economic Recovery
With the spread between value stock and growth stock valuations historically wide, it may not be a bad time for contrarian investors who want to… Read More »5 Stock Picks For Contrarians To “Nibble At Value” – And Profit From The Post-Pandemic Economic Recovery
Top Stocks To Buy On Worsening U.S.-China Relations, As Identified By AI
As relations between the U.S. and China continue to deteriorate, Artificial Intelligence (“AI”) technology says these stocks are top buys. CLICK HERE.
3 MLPs Offering Gusher Payouts At Bottom-Of-The-Barrel Prices
The economic impact of the coronavirus pandemic on the energy sector has presented investors with the opportunity to pick up high-yielding master limited partnerships (MLPs)… Read More »3 MLPs Offering Gusher Payouts At Bottom-Of-The-Barrel Prices
7 Interesting – And Inexpensive – Foreign Stock Ideas To Overcome “Home Bias”
Don’t ditch diversification at the border. With most U.S. investors maintaining too much “home bias” in their portfolios, here are seven compelling foreign stocks to… Read More »7 Interesting – And Inexpensive – Foreign Stock Ideas To Overcome “Home Bias”
Blue-Chip Buys For A Not-Your-Typical Earnings Season
How can investors position themselves heading into what is sure to be a not-your-typical earnings season? Many recent analyst upgrades are directly recommending buying shares… Read More »Blue-Chip Buys For A Not-Your-Typical Earnings Season
The Newest Coronavirus Stock
With its drug candidate having demonstrated antiviral activity against the novel coronavirus in independent laboratory testing, this small-cap biotech joins the ever-growing list of coronavirus… Read More »The Newest Coronavirus Stock
The Key Number To Study In Vaccine Study Results
Whether it’s for COVID-19 or any other disease or disorder, there’s one key number that investors need to focus on when it comes to study… Read More »The Key Number To Study In Vaccine Study Results
An Ideal Strategy For MedTech
While the deferral of elective medical/surgical procedures amid the coronavirus crisis has hit a number of MedTech names hard, there are also some fundamentally strong… Read More »An Ideal Strategy For MedTech